Against the backdrop of the rapid development of precision medicine and immunotherapy, CAR-T cell therapy has become one of the most groundbreaking technologies in the field of cancer treatment. Particularly in hematologic malignancies, this therapy has brought the possibility of long-term remission and even “functional cure” to some patients with relapsed or refractory disease.

A deeper understanding of the mechanisms of action of CAR-T cell therapy not only helps clarify its clinical value but also provides insight into the future direction of cell-based therapies.

What Is CAR-T Cell Therapy?

CAR-T (Chimeric Antigen Receptor T-cell) therapy is a personalized cellular immunotherapy technology. Its core concept is to genetically modify a patient’s own T cells so that they can precisely recognize and eliminate tumor cells.

This treatment approach generally involves the following key steps:

● Collecting T cells from the patient

● Using gene transduction to enable T cells to express chimeric antigen receptors (CARs)

● Expanding the modified cells ex vivo

● Reinfusing the engineered T cells back into the patient

● The modified T cells continuously recognize and destroy tumor cells

From a therapeutic perspective, CAR-T therapy essentially represents “immune system reprogramming,” meaning that it enhances the body’s own immune response to achieve antitumor effects.

Mechanism of CAR-T Cell Therapy: Precise Recognition and Tumor Cell Killing

At the mechanistic level, one of the most distinctive features of CAR-T therapy is its ability to bypass the traditional antigen-presentation process. Under normal circumstances, T cells must recognize antigens through the major histocompatibility complex (MHC). However, CAR-T cells can directly identify specific antigens on the surface of tumor cells, thereby improving immune-mediated cytotoxic efficiency.

Its core mechanisms include:

1️⃣ Antigen-Specific Recognition

The antibody-like domain within the CAR structure can directly bind to tumor-associated antigens. For example, CD19 is commonly expressed in many B-cell malignancies. This mode of recognition is highly specific and can significantly reduce damage to normal tissues.

2️⃣ T-Cell Activation and Proliferation

When CAR-T cells bind to tumor antigens, intracellular signaling pathways are activated, leading to:

● Rapid T-cell proliferation

● Enhanced cytotoxic activity

● Secretion of various cytokines (such as IL-2 and IFN-γ)

This process enables CAR-T cells to generate a sustained immune response within the body.

3️⃣ Direct Tumor Cell Killing

Activated CAR-T cells can induce tumor cell apoptosis by releasing perforin and granzymes. They can also enhance cytotoxic effects through additional pathways such as Fas/FasL signaling. This multi-mechanistic killing strategy contributes to deeper treatment responses.

4️⃣ Formation of Immune Memory

Some CAR-T cells can differentiate into memory T cells and persist long-term in the body. This allows continuous immune surveillance and elimination of residual tumor cells, which is one of the key reasons CAR-T therapy can achieve durable remissions.

Representative CAR-T Therapies

Several CAR-T products have been approved globally, mainly for the treatment of hematologic malignancies, including:

● Tisagenlecleucel

● Axicabtagene ciloleucel

These therapies have been used in patients with difficult-to-treat cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma. With ongoing technological advancements, CAR-T therapy is also being explored for use in solid tumors.

Advantages of CAR-T Therapy

From a treatment strategy perspective, CAR-T therapy offers multiple advantages:

● Highly precise tumor-targeting capability

● A single treatment may provide long-lasting efficacy

● A potential option for patients who have failed conventional therapies

● Represents the future direction of personalized cellular therapy

These characteristics position CAR-T therapy as an important treatment paradigm following targeted therapy and immune checkpoint inhibitors. In addition, in areas such as access to innovative oncology medicines and supply chain support, professional pharmaceutical platforms like Dengyue Pharma are continuously improving their service systems to help healthcare institutions implement advanced immunotherapy strategies more efficiently.

Safety Considerations and Challenges

Despite its remarkable efficacy, CAR-T therapy still faces several clinical challenges, including immune-related adverse events such as cytokine release syndrome (CRS) and neurotoxicity. Moreover, high treatment costs, complex manufacturing processes, and difficulties in identifying optimal targets for solid tumors have limited its broader application.

Therefore, optimizing CAR design, improving manufacturing workflows, and exploring combination treatment strategies have become key research priorities.

Conclusion

Overall, CAR-T cell therapy fundamentally reshapes cancer immunotherapy by genetically engineering T cells to achieve precise tumor antigen recognition, sustained proliferation, and long-term immune surveillance.

In the future, with the development of next-generation CAR-T technologies, universal cell products, and the discovery of new tumor targets, CAR-T therapy is expected to play an increasingly important role across a wider range of cancers and become a critical component of precision oncology treatment systems.